Your browser is no longer supported. Please, upgrade your browser.
IMRA [NASD]
IMARA Inc.
Index- P/E- EPS (ttm)- Insider Own22.52% Shs Outstand17.35M Perf Week-6.18%
Market Cap217.36M Forward P/E- EPS next Y-3.84 Insider Trans-0.16% Shs Float14.95M Perf Month-6.18%
Income- PEG- EPS next Q-0.84 Inst Own83.10% Short Float4.68% Perf Quarter-37.07%
Sales- P/S- EPS this Y-107.00% Inst Trans13.55% Short Ratio5.62 Perf Half Y-49.98%
Book/sh5.46 P/B2.36 EPS next Y-0.50% ROA- Target Price- Perf Year-
Cash/sh5.70 P/C2.26 EPS next 5Y- ROE- 52W Range11.85 - 62.71 Perf YTD-41.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-80.07% Beta-
Dividend %- Quick Ratio18.80 Sales past 5Y- Gross Margin- 52W Low5.49% ATR0.65
Employees16 Current Ratio18.80 Sales Q/Q- Oper. Margin- RSI (14)34.93 Volatility6.12% 4.65%
OptionableNo Debt/Eq0.00 EPS Q/Q-23.70% Profit Margin- Rel Volume0.46 Prev Close12.90
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume124.68K Price12.50
Recom1.30 SMA20-8.11% SMA50-25.39% SMA200-45.64% Volume57,154 Change-3.10%
Aug-17-20Upgrade Citigroup Neutral → Buy $34 → $30
Jun-30-20Downgrade Citigroup Buy → Neutral $30 → $34
Apr-06-20Initiated SVB Leerink Outperform $25
Apr-06-20Initiated Morgan Stanley Overweight $35
Apr-06-20Initiated Cowen Outperform $25
Feb-19-21 07:00AM  
Jan-20-21 07:00AM  
Jan-06-21 05:21PM  
07:00AM  
Dec-10-20 01:01AM  
Dec-07-20 07:00AM  
Nov-30-20 10:36PM  
07:00AM  
Nov-17-20 07:00AM  
Nov-05-20 07:00AM  
Oct-31-20 08:00AM  
Oct-29-20 07:00AM  
Oct-16-20 07:00AM  
Sep-02-20 07:00AM  
Aug-25-20 07:00AM  
Aug-14-20 08:26AM  
07:00AM  
Aug-13-20 04:01PM  
Aug-07-20 07:00AM  
Jul-30-20 07:00AM  
Jun-29-20 04:01PM  
Jun-25-20 07:00AM  
Jun-24-20 07:00AM  
Jun-22-20 01:57PM  
Jun-13-20 08:44AM  
Jun-12-20 07:46AM  
07:00AM  
May-21-20 07:00AM  
May-07-20 07:00AM  
May-06-20 07:00AM  
May-04-20 07:00AM  
Apr-23-20 07:00AM  
Mar-11-20 09:57PM  
Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ballal Rahul D.Chief Executive OfficerDec 17Option Exercise3.154,99915,7474,999Dec 21 04:47 PM
Ballal Rahul D.Chief Executive OfficerDec 17Sale25.004,999124,9750Dec 21 04:47 PM
GRAY MICHAELCFO & COODec 11Option Exercise4.921,2506,1501,250Dec 15 04:26 PM
GRAY MICHAELCFO & COODec 11Sale25.001,25031,2500Dec 15 04:26 PM